Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right.
MarketWatch.com - Top Stories, MarketWatch
Tue, 06/19/2018 - 10:18am
Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right.